Data from Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study

MLA

Jochen H. Lorch, et al. Data from Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-Refractory Thyroid Cancer: A Phase II Study. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.c.6526016.

APA

Jochen H. Lorch, Pasi A. Jänne, Stephanie L. Lee, Ellen Marqusee, Matthew Nehs, Tom Thomas, Krystof Misiwkeiwicz, Francis D. Moore, Erik K. Alexander, Sewanti A. Limaye, Anne O’Neill, Guilherme Rabinowits, Maria E. Cabanillas, Stefan Kraft, Robert I. Haddad, Antonio Calles, Justine A. Barletta, Lori J. Wirth, Nicole G. Chau, … Glenn J. Hanna. (2023). Data from Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. https://doi.org/10.1158/1078-0432.c.6526016

Chicago

Jochen H. Lorch, Pasi A. Jänne, Stephanie L. Lee, Ellen Marqusee, Matthew Nehs, Tom Thomas, Krystof Misiwkeiwicz, et al. 2023. “Data from Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-Refractory Thyroid Cancer: A Phase II Study,” March. doi:10.1158/1078-0432.c.6526016.